Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (108443)	7/17/2007 11:43:03 PM
From: LowtherAcademy	Read Replies (1) \| Respond to of 132070

The Black Adder was always viewed as an insufferable vile little man to his family and class equals. Flashy was a decorated and knighted hero of the Empire to his betters "Good olde Harry,What?). Lots of similar characteristics, but, ultimately Black Adder (much like a infamous Chimp) was born to privilege, whereas Flashy had invent the hero mantle with bluff charade (which he was ever mindful of). Also, much like the aforementioned Chimp, both kept score and savored laying on a good helping of cold revenge on those that had gained at their expense, gggg. Regards, Lew

To: Knighty Tin who wrote (108443)	7/18/2007 8:15:40 AM
From: Broken_Clock	Read Replies (2) \| Respond to of 132070

California psychologist Yang wins World Series of Poker By RYAN NAKASHIMA, Associated Press Writer July 18, 2007 LAS VEGAS (AP) -- Jerry Yang, a 39-year-old psychologist who uses his professional training in his card-playing arsenal, won the top prize Wednesday of $8.25 million at the World Series of Poker. Yang vaulted quickly from eighth to the chip lead soon after play began Tuesday afternoon. He knocked out seven of the eight other players at the final table, reminiscent of last year when Jamie Gold ran over his opponents. The main difference, Yang did it from the back of the pack. "The only way I would win this tournament is to be aggressive from the very beginning and that's exactly what I did," he said. An ethnic Hmong person who grew up poor in Laos, Yang said before the final table began that he would donate 10 percent of his winnings to charity, including the Make-A-Wish Foundation, Feed the Children, the Ronald McDonald House and his alma mater, Loma Linda University. He won his way into the main event from a $225 satellite tournament at the Pechanga Resort & Casino in Temecula and only began playing poker two years ago. Yang began heads up play with a giant chip lead against Tuan Lam, a 40-year-old professional online poker player from Mississauga, Ontario. Yang had 104.5 million in chips to Lam's 23.0 million. On the last hand, with a huge mound of cash deposited on the felt, Lam moved all-in with an ace and queen of diamonds and Yang called with pocket eights. When a queen, five and nine came on the flop, it looked like Lam, waving a Canadian flag, would be on the verge of a miracle comeback, making a pair of queens for the lead. But a seven on the turn and a six on the river gave Yang a straight, sealing a win in which he dominated the final table from the moment the nine finalists sat down. "I've seen the miracles of God with my own eyes," Yang said. "I did a lot of bluffing also." Lam earned $4,840,981 for his second place finish. Play at the final table began at noon in Las Vegas and didn't finish till nearly 4 a.m. The finalists ranged in age from 22 to 62, and hailed from five nations: the U.S., Canada, Russia, England and South Africa. By birthplace, players also were from Laos, Vietnam and Denmark. Each had their section of fans in the audience, and the arena took on the air of the Olympics as supporters broke out into national songs every time their player won a big hand. "The final table says a lot about the globality of poker and the globality of our fans," said Jeffrey Pollack, World Series of Poker commissioner for event owner Harrah's Entertainment Inc. The nine players who began the day were all that remained from a field of 6,358 players that began to play down in stages July 6. Everyone paid or won $10,000 to enter the main event, the biggest poker tournament of the year.

To: Knighty Tin who wrote (108443)	7/18/2007 9:15:44 AM
From: Pogeu Mahone	Respond to of 132070

Aethlon Medical Announces Cancer Treatment Discovery Jul 18, 2007 7:00:00 AM Copyright Business Wire 2007 SAN DIEGO--(BUSINESS WIRE)-- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that researchers have discovered the Aethlon Hemopurifier(R) is effective in capturing particles that suppress the immune response in cancer patients. The particles, known as exosomes, are released by solid tumors, lymphomas, and leukemia. Exosomes induce T-cell apoptosis (programmed cell death), and block T-cell signaling, proliferation, and cytokine production. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients. In studies led by Dr. Douglas Taylor at the University of Louisville, 60% of circulating exosomes were removed from the blood of ovarian cancer patients during first pass (approximately 10-minutes) through a small scale Hemopurifier(R). The capture data was consistent over the course of five different studies. The ability to reduce circulating exosomes would likely reverse immune suppression and increase patient responsiveness to both immunotherapy and chemotherapy. Dr. Taylor is a recognized authority on the causative effects of immune suppression in cancer patients. He is the credited with the initial characterization of exosomes and is the leading peer reviewed author on the subject. Based on initial study observations, the Aethlon Hemopurifer(R) is positioned to address the unmet medical need of inhibiting exosome production in cancer patients. As a result, Aethlon will increase the focus of its treatment opportunities to include both the infectious disease and cancer markets. Related to this news, a detailed audio presentation by Dr. Taylor and Aethlon Chairman and CEO, James A. Joyce can be accessed online at: www.aethlonmedical.com/news/cancer.htm. About Aethlon Medical Aethlon Medical is the developer of the Hemopurifier(R), a first-in-class medical device to treat infectious disease. The Hemopurifier(R) addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier(R) are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier(R) in a 24-treatment human study and has received approval to continue further humans studies at The Fortis Hospital in India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier(R) as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information on Aethlon Medical and its Hemopurifier(R) technology can be accessed at www.aethlonmedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. Source: Aethlon Medical, Inc.